Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 5/20 | 0.37 |
| ▸ | THRA | P10827 | 6/20 | 0.36 |
| ▸ | THRB | P10828 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924480 | 0.83 | LRRK2 (0.47) | LRRK2ALDH1A1PKMMAPTKMT2A | |
| SCHEMBL4919003 | 0.81 | LRRK2 (0.46) | LRRK2ALDH1A1PKMMEN1MAPT | |
| SCHEMBL4917837 | 0.78 | ALDH1A1 (0.43) | LRRK2ALDH1A1PKMMEN1KMT2A | |
| SCHEMBL14007339 | 0.72 | MAPT (0.47) | LRRK2ALDH1A1PKMMEN1MAPT | |
| SCHEMBL4918991 | 0.71 | ALDH1A1 (0.51) | LRRK2ALDH1A1PKMMEN1MAPT | |
| SCHEMBL4921837 | 0.70 | LRRK2 (0.43) | LRRK2ALDH1A1PKMMAPTKDM4E | |
| SCHEMBL4928786 | 0.69 | ALDH1A1 (0.52) | LRRK2ALDH1A1PKMMEN1MAPT | |
| SCHEMBL4927165 | 0.68 | ALDH1A1 (0.50) | LRRK2ALDH1A1PKMMEN1MAPT | |
| SCHEMBL4918837 | 0.67 | LMNA (0.48) | LRRK2ALDH1A1PKMMAPTKMT2A | |
| SCHEMBL14007322 | 0.67 | LRRK2 (0.44) | LRRK2ALDH1A1PKMMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| EP-1765814-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006003096-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | GLP1R, GIPR, GCGR | LRRK2 327/4885ALDH1A1 2002/4885PKM 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.